Meta going all in – More cracks in the AI Capex bubble

In August 2025, I published my first Weekly fully dedicated to this topic. It became my second most read Weekly so far. I gave it the name “Artificial Intelligence meets natural stupidity – and a potential winner no one is counting on”. I introduced my readers to the growing Capex mania of the Big Tech companies, focussing on Meta, and concluding that Apple might turn out to be the winner thanks to avoiding doing stupid things. While the mania continues at even more extreme levels, the risks for a big burst have only increased.

Continue reading

Is now the time to rotate into defensive stocks?

This question pops up frequently. Some people ask it more often, others less so. The ongoing bull market started in 2009 and was only briefly interrupted a few times. Every dip gets bought, and on we go. We haven’t seen a recession with an enduring and nasty bear market. Many investors nowadays do not even know what that is – the last one is simply too far away. This Weekly is not about market timing, but about bringing some thoughts in order, cleaning up with a few misbeliefs, and challenging the composition of one’s stock portfolio.

Continue reading

Side Effect of AI: The Storage Bubble + New Research Report

It is no secret that AI as a topic, its various applications, and in consequence stocks related to AI are receiving much attention. More and more challenge the sustainability of this rapid rise over the last few years, especially as the question of profitability remains unanswered. While everyone is aware of stocks like Nvidia, Oracle or critical suppliers like Micron, as well as multiple AI chatbots, the AI mania has pulled up an otherwise boring sub-segment: storage stocks. Is this justified? All my paid-members receive my latest stock idea: a growing franchise that’s set to dominate the eye care market.

Continue reading

Post-Exit Returns of my closed cases analyzed

After having closed a stock idea and after some time passes, it is interesting to take another look at it. An obvious question is the return since the exit. More importantly, though, is what can I learn from the exit and from the subsequent movements, up or down? To answer that, I am for the first time ever unveiling all my closed cases that once were member-exclusive stock ideas. With only one exception, I have not re-activated any case. How did they perform post-exit and what do I distill out of this exercise?

Continue reading

Investing in stocks of bankrupt companies + new research report

Investing in stocks of companies that went bankrupt, seriously? Seriously! What at first sounds like a recipe for disaster, indeed can be a lucrative endeavor. A bankrupt company is not the same as the ceasing of operations. Indeed, often it is even the case that companies go into bankruptcy restructuring while everyday operations continue. This area can be a great treasure trove to fish for potential multi-baggers where others don’t bother due to negative associations. A premier on Financial Engineering: My Premium PLUS members receive my latest stock idea – a pick that recently emerged from bankruptcy – with the potential to multi-bag.

Continue reading

3 Years of Breaking the Code of “Safe” Stocks and True Value

It’s been three years (and a month) since I launched Financial-Engineering.net in August 2022 to share my unfiltered thoughts on stocks, their valuations, risks like dividend cuts, and my best ideas that survive my rigorous research process. In past anniversary posts, I’ve offered food-for-thought insights. Today, I’m cracking the myth of “safe” stocks.

Continue reading

Artificial Intelligence meets natural stupidity – and a potential winner no one is counting on

Is AI the biggest bubble we have ever witnessed? There are many voices claiming so, while others are of the view mankind has reached a new plateau in its evolution. As this is not a new topic per se, and my skepticism is well-known among my readers, I am not going to drill deeper on this front. However, there is a subtopic that deserves much more attention than it actually gets. Maybe because it is so boring and likely ahead of its time, the majority currently does not care. I do, though. And you probably should either.

Continue reading

Are we seeing (again) the Erosion of Brand Values? + new research report

Many investors seek “moats”, or key differentiators that keep competitors at a distance. These “high-quality stocks” not seldom trade at premium valuations. At least for as long as this superior status is perceived. One such edge can be a brand. Well-known names create a barrier which in the best case even keeps new entrants out of the game entirely. However, it is no secret that brands come and go. Are we seeing another washout where once thought-to-be indispensable names are struggling for a reason? All my paid members receive my latest stock idea. It is a company with a strong market position where the brand name is irrelevant, for most even unknown.

Continue reading

(Un)Safety first: The Drama of Sarepta Therapeutics

Biotech stocks are known for two things: either being graveyards for shareholders’ money or generating outsized returns – especially if they become multi-baggers (assuming one is positioned before the retail crowd discovers such ideas). While not every biotech stock turns out to be a do-or-die binary bet, it is safe to say that those stocks with big moves catch much attention – no matter the direction. Sarepta Therapeutics is such a case. It has even offered its shareholders both, an astronomical rise and a fall from grace despite generating billion-USD sales. A case study worth to have heard of.

Continue reading

PVH Corp.: Trading at 6x earnings – still not a buy

While it likely makes sense to be cautious when a stock trades at a high valuation multiple, the case of PVH Corp. might raise some eyebrows – at least at first sight. The company owns two well-known apparel brands, has been constantly profitable, is generating healthy free cash flow and even buying back its own shares aggressively at a low valuation, seemingly generating strong shareholder value. Shares, however, only trade at a 6x price to earnings ratio. I’ll tell you while this likely is still not a bargain.

Continue reading